Progenics Pharmaceuticals, Inc. |
(Exact name of registrant as specified in
its charter) |
Delaware
|
|
000-23143
|
|
13-3379479
|
(State or Other Jurisdiction of Incorporation)
|
|
(Commission File
Number) |
|
(I.R.S. Employer
Identification No.) |
777 Old Saw Mill River Road, Tarrytown, New York | 10591 |
|||
(Address of principal executive offices) | (Zip Code) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement
Item 9.01 Financial Statements and Exhibits
(c) | |||
EXHIBIT NUMBER | DESCRIPTION | ||
Exhibit 10.28 | Amendment to Exclusive Sub-License Agreement between Progenics Pharmaceuticals, Inc. and UR Labs, Inc., dated September 21, 2001 (filed herewith). |
|
PROGENICS PHARMACEUTICALS, INC.
|
|
|
|
|
|
||
|
|
|
|
|
By: /s/ ROBERT A.
MCKINNEY
|
|
|
Name: Robert
A. McKinney
|
|
|
Title: Vice
President, Finance and Operations
|